• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why IMARA Shares Are Trading Higher By Over 13%; Here Are 22 Stocks Moving Premarket

    10/14/22 7:34:37 AM ET
    $ATXI
    $BDTX
    $CNXA
    $DBGI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ATXI alert in real time by email

    Gainers

    • Connexa Sports Technologies Inc. (NASDAQ:CNXA) shares rose 80.1% to $0.4161 in pre-market trading after declining around 7% on Thursday. CONNEXA, last month, announced a $5.0 million private placement.
    • Zovio Inc (NASDAQ:ZVO) rose 16.8% to $0.1690 in pre-market trading.
    • Eargo, Inc. (NASDAQ:EAR) rose 16.5% to $0.8269 in pre-market trading. Eargo announced that the record date for its proposed rights offering is October 24, 2022.
    • FedNat Holding Company (NASDAQ:FNHC) rose 16.3% to $0.4089 in pre-market trading after jumping over 56% on Thursday.
    • IMARA Inc. (NASDAQ:IMRA) rose 13.2% to $2.92 in pre-market trading. Enliven Therapeutics and Imara announced a merger agreement.
    • Avenue Therapeutics, Inc. (NASDAQ:ATXI) shares rose 10.3% to $2.68 in pre-market trading after declining over 4% on Thursday.
    • WM Technology, Inc. (NASDAQ:MAPS) shares rose 9.9% to $1.88 in pre-market trading.
    • Quanergy Systems, Inc. (NYSE:QNGY) shares rose 9.3% to $2.00 in pre-market trading after dipping 16% on Thursday.
    • CarLotz, Inc. (NASDAQ:LOTZ) rose 8% to $0.29 in pre-market trading.
    • Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) rose 7.7% to $3.47 in pre-market trading.
    • Digital Brands Group, Inc. (NASDAQ:DBGI) shares rose 7.3% to $0.1180 in pre-market trading after the company finalizes new agreement for $20 million revenue Sunnyside, LLC acquisition, scheduled to close in November.
    • Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) rose 7.1% to $1.36 in pre-market trading after declining over 5% on Thursday.
    • Zai Lab Limited (NASDAQ:ZLAB) rose 6% to $30.20 in pre-market trading. Seagen and Zai Lab recently announced an exclusive collaboration and license agreement for the development and commercialization of TIVDAK (tisotumab vedotin-tftv) in mainland China, Hong Kong, Macau, and Taiwan.

    Don’t forget to check out our premarket coverage here .


    Losers

    • Novo Integrated Sciences, Inc. (NASDAQ:NVOS) fell 38.7% to $0.46 in pre-market trading after the company announced pricing of $2 million public offering of 4 million units at $0.50 per unit.
    • Nuwellis, Inc. (NASDAQ:NUWE) fell 13.3% to $0.2880 in pre-market trading after dropping 10% on Thursday. Nuwellis recently announced results of the AVOID-HF clinical study analysis at the 2022 HFSA meeting, showing a "statistically superior clinical benefit of Aquadex therapy in reducing heart failure events and mortality."
    • Nutex Health Inc. (NASDAQ:NUTX) fell 10.8% to $0.8512 in pre-market trading after jumping 72% on Thursday. Nutex recently provided a corporate update.
    • Gravitas Education Holdings, Inc. (NYSE:GEHI) shares fell 9.2% to $13.62 in pre-market trading after surging around 14% on Thursday.
    • Romeo Power, Inc. (NYSE:RMO) shares fell 8.7% to $0.33 in pre-market trading. Nikola completed exchange offer to acquire Romeo Power common stock.
    • Oblong, Inc. (NASDAQ:OBLG) shares fell 7.7% to $0.2123 in pre-market trading after climbing over 26% on Thursday.
    • Qualigen Therapeutics, Inc (NASDAQ:QLGN) fell 7.1% to $0.2510 in pre-market trading.
    • Plus Therapeutics, Inc. (NASDAQ:PSTV) fell 6.7% to $0.4750 in pre-market trading. JonesTrading, last week, initiated coverage on the stock with a Buy rating and $5 price target.
    • China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) shares fell 6.6% to $0.6180 in pre-market trading. On October 11, China SXT Pharmaceuticals received the funds from Mr. Xiao who previously agreed to purchase 1,625,798 shares of the company, par value $0.08/share at a per share purchase price of $1.35.
    Get the next $ATXI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATXI
    $BDTX
    $CNXA
    $DBGI

    CompanyDatePrice TargetRatingAnalyst
    PLUS THERAPEUTICS Inc.
    $PSTV
    2/3/2026$2.00Buy
    Lake Street
    Black Diamond Therapeutics Inc.
    $BDTX
    12/3/2025Buy → Neutral
    Guggenheim
    Black Diamond Therapeutics Inc.
    $BDTX
    11/18/2025$9.00Overweight
    Piper Sandler
    Black Diamond Therapeutics Inc.
    $BDTX
    10/16/2025$8.00Buy
    Stifel
    Black Diamond Therapeutics Inc.
    $BDTX
    9/4/2025$8.00Buy
    Guggenheim
    PLUS THERAPEUTICS Inc.
    $PSTV
    9/3/2025$5.00Hold → Buy
    D. Boral Capital
    Zai Lab Limited
    $ZLAB
    8/25/2025$52.00Buy
    Jefferies
    Black Diamond Therapeutics Inc.
    $BDTX
    7/1/2025$11.00Outperform
    Raymond James
    More analyst ratings

    $ATXI
    $BDTX
    $CNXA
    $DBGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Plus Therapeutics with a new price target

    Lake Street initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $2.00

    2/3/26 8:52:26 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Black Diamond Therapeutics downgraded by Guggenheim

    Guggenheim downgraded Black Diamond Therapeutics from Buy to Neutral

    12/3/25 12:43:23 PM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler resumed coverage on Black Diamond Therapeutics with a new price target

    Piper Sandler resumed coverage of Black Diamond Therapeutics with a rating of Overweight and set a new price target of $9.00

    11/18/25 8:20:21 AM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATXI
    $BDTX
    $CNXA
    $DBGI
    SEC Filings

    View All

    SEC Form RW filed by PLUS THERAPEUTICS Inc.

    RW - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    3/6/26 4:05:32 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Nutex Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Nutex Health Inc. (0001479681) (Filer)

    3/5/26 4:11:50 PM ET
    $NUTX
    Real Estate

    SEC Form 10-K filed by Nutex Health Inc.

    10-K - Nutex Health Inc. (0001479681) (Filer)

    3/5/26 4:10:58 PM ET
    $NUTX
    Real Estate

    $ATXI
    $BDTX
    $CNXA
    $DBGI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Bates Jon Christian bought $102,532 worth of shares (750 units at $136.71), increasing direct ownership by 15% to 5,638 units (SEC Form 4)

    4 - Nutex Health, Inc. (0001479681) (Issuer)

    11/28/25 2:11:24 PM ET
    $NUTX
    Real Estate

    President and CEO Holst Peter bought $9,500 worth of shares (5,000 units at $1.90), increasing direct ownership by 47% to 15,544 units (SEC Form 4)

    4 - Oblong, Inc. (0000746210) (Issuer)

    11/19/25 3:15:50 PM ET
    $OBLG
    Computer Software: Programming Data Processing
    Technology

    President and CEO Holst Peter bought $18,400 worth of shares (10,000 units at $1.84), increasing direct ownership by 1,838% to 10,544 units (SEC Form 4)

    4 - Oblong, Inc. (0000746210) (Issuer)

    11/17/25 1:12:26 PM ET
    $OBLG
    Computer Software: Programming Data Processing
    Technology

    $ATXI
    $BDTX
    $CNXA
    $DBGI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4.Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter.Closed a $5.0 million private p

    3/10/26 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM

    FULL YEAR 2025 HIGHLIGHTS:Total revenue of $875.3 million for the year 2025 versus $479.9 million for the year 2024, an increase of 82.4%Net income attributable to Nutex Health of $70.8 million for 2025 versus net income of $52.1 million for 2024, an increase of $18.7 millionDiluted EPS of $10.48 for 2025 versus diluted EPS of $9.69 for 2024EBITDA of $168.6 million for 2025 versus $98.8 million for 2024, an increase of 70.6%Adjusted EBITDA of $259.6 million for 2025 versus $102.8 million for 2024, an increase of 152.6%Net cash from operating activities of $248.1 million for 2025HOUSTON, March 5, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), today ann

    3/5/26 6:33:00 PM ET
    $NUTX
    Real Estate

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ATXI
    $BDTX
    $CNXA
    $DBGI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rellas Nicholas Antone was granted 466,309 shares (SEC Form 4)

    4 - WM TECHNOLOGY, INC. (0001779474) (Issuer)

    3/9/26 6:38:38 PM ET
    $MAPS
    Computer Software: Prepackaged Software
    Technology

    SEC Form 3 filed by new insider Rellas Nicholas Antone

    3 - WM TECHNOLOGY, INC. (0001779474) (Issuer)

    3/9/26 6:38:08 PM ET
    $MAPS
    Computer Software: Prepackaged Software
    Technology

    Chief Legal Officer Edmondson Frazor Titus Iii sold $296,745 worth of American Depositary Shares (15,569 units at $19.06), decreasing direct ownership by 82% to 3,517 units (SEC Form 4)

    4 - Zai Lab Ltd (0001704292) (Issuer)

    3/6/26 4:26:10 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXI
    $BDTX
    $CNXA
    $DBGI
    Financials

    Live finance-specific insights

    View All

    Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4.Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter.Closed a $5.0 million private p

    3/10/26 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM

    FULL YEAR 2025 HIGHLIGHTS:Total revenue of $875.3 million for the year 2025 versus $479.9 million for the year 2024, an increase of 82.4%Net income attributable to Nutex Health of $70.8 million for 2025 versus net income of $52.1 million for 2024, an increase of $18.7 millionDiluted EPS of $10.48 for 2025 versus diluted EPS of $9.69 for 2024EBITDA of $168.6 million for 2025 versus $98.8 million for 2024, an increase of 70.6%Adjusted EBITDA of $259.6 million for 2025 versus $102.8 million for 2024, an increase of 152.6%Net cash from operating activities of $248.1 million for 2025HOUSTON, March 5, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), today ann

    3/5/26 6:33:00 PM ET
    $NUTX
    Real Estate

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. FundTickerDistribution Per ShareDistribution Rate30-Day SEC YieldReturn of CapitalEx-Date / Record DatePayment Date1-Month Return1-Year ReturnSince InceptionReturnBitwise COINOption Income Strategy ETFICOI$0.6149255.74 %0.00 %100.00 %02/27/202603/03/2026-12.65 %N/A-25.29 %Bitwise MARAOption Income Strategy ETFIMRA$0.3058725.67 %0.00 %100.00 %02/27/2026

    2/26/26 4:22:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATXI
    $BDTX
    $CNXA
    $DBGI
    Leadership Updates

    Live Leadership Updates

    View All

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    WM Technology, Inc. Appoints Harry DeMott and Brent Cox to Board of Directors and Announces Executive Employment Arrangement with CFO Susan Echard

    WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Harry DeMott and Brent Cox to the Company's Board of Directors, effective February 1, 2026. The Company also announced that Susan Echard will continue to serve as Chief Financial Officer, transitioning from a contracted arrangement to employment with the Company, effective January 30, 2026. "We are pleased to welcome Harry and Brent to WM Technology's Board of Directors. They each bring a combination of cannabis industry perspective, technology fluency, and disciplined capital markets experience," said Do

    2/3/26 5:45:00 PM ET
    $ISPR
    $MAPS
    Medicinal Chemicals and Botanical Products
    Health Care
    Computer Software: Prepackaged Software
    Technology

    $ATXI
    $BDTX
    $CNXA
    $DBGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Avenue Therapeutics Inc.

    SC 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

    11/15/24 4:05:50 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Avenue Therapeutics Inc.

    SC 13G - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

    11/14/24 3:22:45 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Black Diamond Therapeutics Inc.

    SC 13G/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

    11/14/24 1:28:32 PM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care